Drugs / FMXIN002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07228325 | Nov 2025 → Mar 2026 overdue | allergic disease, anaphylaxis | Nasus Pharma | Enrolling by invitation | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-02-17 | Nasus Pharma | Results Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026 nasuspharma.com ↗
FMXIN002 Epinephrine Intranasal Powder Spray is Stable Throughout 3 Freeze-Thaw Cycles |
| 2024-08-07 | Nasus Pharma | Results Nasus Pharma Announces Ground-Breaking Five Years Stability of its FMXIN002 Nasal Epinephrine Powder for Severe Allergy and Anaphylaxis nasuspharma.com ↗
Epinephrine base was 97.5% at 5 years well within the defined limits (95-105% ICHQ1 ). |
| 2023-12-05 | Nasus Pharma | Results Nasus Pharma Announces Positive Clinical Results of Recent Phase 2 Study With FMXIN002 Intranasal Epinephrine nasuspharma.com ↗
FMXIN002 demonstrated clear and meaningful advantage both in the pharmacokinetic profile of the first 20 minutes and in the number of patients reaching drug plasma clinical threshold of Epinephrine. |
| 2021-06-23 | Nasus Pharma | Results Nasus Pharma Announces Positive Results from a Pilot Clinical Study of FMXIN002 Intranasal Powder Epinephrine Spray in nasuspharma.com ↗
The results of the study with FMXIN002 powder intranasal Epinephrine show that it can provide a safer and more effective rescue for the emergency treatment of life- threatening allergic reactions by providing an easy-to-use device and quicker absorption of Epinephrine |
All press releases naming this drug 5 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FMXIN002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07228325 ↗ |
| Route | Intranasal | “Single dose of FMXIN002 epinephrine microspheres powder for nasal application, 4.0 mg, at normal conditions.” NCT07228325 ↗ |